AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

AEZS has been the topic of several other reports. HC Wainwright set a $3.00 target price on AEterna Zentaris and gave the company a “buy” rating in a report on Wednesday, July 5th. Maxim Group set a $2.00 target price on AEterna Zentaris and gave the company a “buy” rating in a report on Monday, May 1st.

Shares of AEterna Zentaris (NASDAQ AEZS) remained flat at $1.03 during midday trading on Tuesday. The stock had a trading volume of 444,387 shares. AEterna Zentaris has a 1-year low of $0.78 and a 1-year high of $5.59. The company’s market capitalization is $14.76 million. The company has a 50-day moving average of $0.98 and a 200-day moving average of $2.43.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. AEterna Zentaris had a negative return on equity of 425.52% and a negative net margin of 2,732.69%. The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.85 million. During the same period last year, the company earned ($0.37) earnings per share. The business’s revenue was up 8.3% compared to the same quarter last year. Analysts expect that AEterna Zentaris will post ($1.39) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/07/11/aeterna-zentaris-inc-aezs-rating-increased-to-hold-at-zacks-investment-research.html.

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.